Affimed NV (AFMD) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Affimed NV

NASDAQ | AFMD

0.63

USD

-0.08 (-11.24%)

AT CLOSE (AS OF Apr 3, 2025)

$12M

MARKET CAP

P/E Ratio

-4.92

EPS

52 Week High

$0.69

52 Week Low

LIFE SCIENCES

Sector

AFMD Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

AFMD Technicals

Tags:

AFMD Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (EUR)
Gross Profit	$8.3M
Total Revenue	$8.3M
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	-$107M
Selling General And Administrative	$25M
Research And Development	$95M
Operating Expenses	$115M
Investment Income Net	-
Net Interest Income	$238K
Interest Income	$509K
Interest Expense	$1.8M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$1.7M
Income Before Tax	-$106M
Income Tax Expense	$3K
Interest And Debt Expense	-
Net Income From Continuing Operations	-$106M
Comprehensive Income Net Of Tax	-
Ebit	-$104M
Ebitda	-$102M
Net Income	-$106M

Revenue & Profitability

Earnings Performance

AFMD Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2023)

Field	Value (EUR)
Total Assets	$97M
Total Current Assets	$84M
Cash And Cash Equivalents At Carrying Value	$39M
Cash And Short Term Investments	$39M
Inventory	$463K
Current Net Receivables	-
Total Non Current Assets	$13M
Property Plant Equipment	-
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	$25K
Intangible Assets Excluding Goodwill	$25K
Goodwill	-
Investments	-
Long Term Investments	-
Short Term Investments	$34M
Other Current Assets	$5.5M
Other Non Current Assets	-
Total Liabilities	$39M
Total Current Liabilities	$26M
Current Accounts Payable	-
Deferred Revenue	-
Current Debt	-
Short Term Debt	$6.4M
Total Non Current Liabilities	$13M
Capital Lease Obligations	$7.2M
Long Term Debt	$6.3M
Current Long Term Debt	$5.8M
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$19M
Other Current Liabilities	-
Other Non Current Liabilities	-
Total Shareholder Equity	$58M
Treasury Stock	-
Retained Earnings	-$536M
Common Stock	$1.5M
Common Stock Shares Outstanding	$15M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (EUR)
Operating Cashflow	-$110M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	-
Change In Operating Assets	-
Depreciation Depletion And Amortization	$1.7M
Capital Expenditures	$3.7M
Change In Receivables	-
Change In Inventory	$100K
Profit Loss	-
Cashflow From Investment	-
Cashflow From Financing	-$6.2M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	-
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$106M

yearly Income Statement (As of Dec 31, 2023)

Field	Value (EUR)
Gross Profit	$8.3M
Total Revenue	$8.3M
Cost Of Revenue	-
Costof Goods And Services Sold	-
Operating Income	-$107M
Selling General And Administrative	$25M
Research And Development	$95M
Operating Expenses	$115M
Investment Income Net	-
Net Interest Income	$238K
Interest Income	$509K
Interest Expense	$1.8M
Non Interest Income	-
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$1.7M
Income Before Tax	-$106M
Income Tax Expense	$3K
Interest And Debt Expense	-
Net Income From Continuing Operations	-$106M
Comprehensive Income Net Of Tax	-
Ebit	-$104M
Ebitda	-$102M
Net Income	-$106M

AFMD Profile

Affimed NV Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Affimed NV, a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The company is headquartered in Heidelberg, Germany.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217
PTIX	$0.43	91.50%	$4.04M	173,208,693

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.60	-0.95%	$308.32B	7,033,051
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.76	0.18%	$220.07B	7,844,359

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.43	91.50%	$4.04M	173,208,693
MRM	$0.65	74.84%	$2.91M	51,693,935

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	20,249,631
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

AFMD $0.63 (-11.24%) Quote details